

Resource Summary Report

Generated by [NIF](#) on Sep 3, 2026

TIM-3 (D5D5R™) XP® Rabbit mAb

RRID:AB_2716862

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 45208, RRID:AB_2716862

Antibody Information

URL: http://antibodyregistry.org/AB_2716862

Proper Citation: Cell Signaling Technology Cat# 45208, RRID:AB_2716862

Target Antigen: TIM-3

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IP, IHC-Bond, IHC-P, F
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: TIM-3 (D5D5R™) XP® Rabbit mAb

Description: This recombinant monoclonal targets TIM-3

Target Organism: human

Clone ID: D5D5R™

Antibody ID: AB_2716862

Vendor: Cell Signaling Technology

Catalog Number: 45208

Record Creation Time: 20231110T033802+0000

Record Last Update: 20260829T161101+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for TIM-3 (D5D5R™) XP® Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Podaza E, et al. (2026) Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. Cell reports methods, 6(6), 101339.

Marceaux C, et al. (2026) TNF-?-mediated myeloid-instructed CD14+CD4+ T cells are associated with poor survival in lung adenocarcinoma. Cell reports. Medicine, 7(2), 102593.

Liu HM, et al. (2025) Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. Cell reports. Medicine, 6(2), 101930.

Liu F, et al. (2025) Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization. Cell genomics, 5(7), 100888.

Zhu B, et al. (2025) Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer cell, 43(6), 1125.

Digomann D, et al. (2025) Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. iScience, 28(11), 113871.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer cell, 42(1), 135.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell reports. Medicine, 5(2), 101397.

Quek C, et al. (2024) Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell reports, 43(7), 114392.

Wang Y, et al. (2023) Intratumoral erythroblastic islands restrain anti-tumor immunity in hepatoblastoma. *Cell reports. Medicine*, 4(5), 101044.

Wang Z, et al. (2023) Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. *Cell metabolism*, 35(7), 1209.

Ausejo-Mauleon I, et al. (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. *Cancer cell*, 41(11), 1911.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN- γ axis. *Cell reports*, 42(8), 112944.

Guo Q, et al. (2022) Cancer cell intrinsic TIM-3 induces glioblastoma progression. *iScience*, 25(11), 105329.

Li K, et al. (2022) Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. *Cancer cell*, 40(11), 1374.

Wingrove E, et al. (2019) Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. *Cell reports*, 27(4), 1277.

de Mingo Pulido Á, et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. *Cancer cell*, 33(1), 60.